Melanoma targeted therapies dabrafenib and trametinib cross the placental barrier in ex vivo human placental perfusions [0.03%]
达拉菲尼和曲美替尼通过体外人胎盘灌流模型中的胎盘屏障
Estelle Heggarty,David Combarel,Hadia Moindjie et al.
Estelle Heggarty et al.
Anna Kasielska-Trojan,Bogusław Antoszewski,Marta Fijałkowska
Anna Kasielska-Trojan
Healthcare resource utilization and economic burden in generalized pustular psoriasis (GPP) among US adults: A large claims database analysis [0.03%]
美国成人泛发性脓疱性银屑病医疗资源利用和经济负担的大型理赔数据库分析
Mark Lebwohl,Bhargav Lakshminarasimhan,Layla Lavasani et al.
Mark Lebwohl et al.
Correction [0.03%]
改正
Glucagon-like Peptide-1 Receptor Agonists in the Adjunctive Treatment of Patients with Hidradenitis Suppurativa: A Systematic Review [0.03%]
胰高血糖素样肽-1受体激动剂辅助治疗毛囊闭锁三联征：系统评价
Abizairie Sánchez-Feliciano,Henry Herrera,Alexandra Charrow et al.
Abizairie Sánchez-Feliciano et al.
Bigger might actually be better: A prospective investigation into the association between body mass index, tumour stage, and recurrence in patients with high-risk primary melanoma [0.03%]
体重指数较高、肿瘤分期及高危型黑色素瘤复发之间的关联研究
Hansa Sharma,Maria Celia B Hughes,Danielle Gavanescu et al.
Hansa Sharma et al.
Response to Quitterie Murat de Montai et al, "Interferon-a biological activity is associated with disease activity and risk of flare in cutaneous lupus erythematosus: A monocentric study of 184 patients" [0.03%]
穆拉特德蒙泰等人关于“干扰素-α生物活性与皮肤狼疮患者疾病活动及病情加重风险相关性单中心研究（184例）”的述评
Zhongyu Chen,Danqi Deng
Zhongyu Chen
Invited Reply to Chen, et al. 'Response to Quitterie Murat de Montai et al, ''Interferon-α biological activity is associated with disease activity and risk of flare in cutaneous lupus erythematosus: A monocentric study of 184 patients" [0.03%]
陈等对吕特里·莫塔尔德蒙泰等人在“干扰素-α 生物活性与盘状红斑狼疮疾病活动度和病情加重风险的相关性：一项针对184例患者的单中心研究”一文的回复
Quitterie Murat de Montai,Laura Perray,Alexis Mathian et al.
Quitterie Murat de Montai et al.
The Sun-Safe Golf Course: Assessing Sun Protection Measures and Educational Resources at Michigan Golf Courses [0.03%]
阳光安全高尔夫球场：评估密歇根州高尔夫球场的防晒措施和教育资源
Madison Gustav,Alexandria Wilson,Jena Jacobs et al.
Madison Gustav et al.
Effectiveness of Tralokinumab for Upadacitinib-Refractory Atopic Dermatitis: 48-week Retrospective Study [0.03%]
关于特拉洛克单抗治疗乌帕替尼耐药性特应性皮炎的疗效：一项为期48周的回顾性研究
Teppei Hagino,Hidehisa Saeki,Eita Fujimoto et al.
Teppei Hagino et al.